Understand the source comparison
Best KLOW Dosage Anti-Inflammatory 2026: Protocol Comparison
1mg weekly MC1R peripheral (macrophages, dendritic cells) 18–25% Minimal (<10%) Systemic inflammation, metabolic research, joint studies Rare (skin darkening <5% of cases) Best starting dose for metabolic or peripheral inflammatory research. Minimal central ef
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 1mg weekly
- MC1R peripheral (macrophages, dendritic cells)
- 18–25%
- Minimal (<10%)
- Systemic inflammation, metabolic research, joint studies
- Rare (skin darkening <5% of cases)
- Best starting dose for metabolic or peripheral inflammatory research. Minimal central effects, predictable biomarker response
- 2mg weekly
- MC1R + MC3R bridging (peripheral + CNS immune cells)
- 28–33%
- Moderate (25–35%)
- Neuroinflammation, chronic pain models, cognitive decline research
- Mild appetite suppression (10–15%), transient nausea (<10%)
- Optimal for neuroinflammatory research. Engages central pathways without oversaturation, measurable BDNF increase
- 3mg weekly
- Full MC1R/MC3R/MC4R saturation (systemic + central + metabolic)
- 35–42%
- High (45–55%)
- Severe systemic inflammation, combined metabolic/neuroinflammatory models
- Nausea (15–20%), injection site darkening (20%), mild lethargy
- Reserved for severe inflammation models or combined research objectives. Side effect trade-offs require monitoring
- 1.5mg biweekly
- MC1R steady-state maintenance
- 15–20% (slower onset)
- Minimal
- Long-term low-grade inflammation maintenance studies
- Alternative dosing for extended protocols where weekly injections aren't practical. Lower peak concentration but sustained trough levels